Interview with Jose Manuel Lezama , General Manager, BSN Medical Mexico
When you joined BSN Medical 3 years ago, what was the roadmap set in place for the growth and development of the company? Which opportunities did the company see in…
Address: Asturias 39. Col. Insurgentes Mixcoac Delegacion Benito Juarez C.P. 03920 México City,Mexico
Tel: 52,55,5482,5400
Web: http://mexico.bsnmedical.com/
BSN medical was established in April 2001 as a 50:50 joint venture between Beiersdorf AG, Hamburg, and Smith & Nephew plc, London due to complementary geographic and channel strengths in the areas of wound care, fracture management, physiotherapy and compression therapy. BSN medical was acquired in 2006 by Montagu Private Equity, a leading private equity investor in the European mid-market, with a large pool of available funds, with values ranging from € 100 million to € 1+ billion. Since then, BSN was developed as a fully independent global player in the health care market. Under Montagu’s ownership BSN medical successfully completed 4 acquisitions, further developed the global independency and continued the portfolio upgrade through highly innovative product launches (e.g. Advanced Wound Care).
BSN medical focuses on developing world-class products that offer high quality solutions for both caregivers and patients.
We are one of the world’s leading suppliers in the medical product segments of casting, bandaging, traditional wound care and compression therapy.
When you joined BSN Medical 3 years ago, what was the roadmap set in place for the growth and development of the company? Which opportunities did the company see in…
It’s been one year since you were appointed as Federal Commissioner of COFEPRIS in March 2011. What have been the biggest challenges you’ve faced within this time? The biggest challenge…
Can you tell us a little about the history of Medix and about the company itself? Medix is a 100% Mexican company created in 1956, and our major strength is…
Apotex has increased production, launched 16 new products last March, and grown significantly in the market. What would you say has been the biggest change in the market over the…
The last time we interviewed you was in 2008. Please can you tell our readers a little bit more about Liomont’s growth drivers and changes over these last four years?…
When we saw you in 2008 we had read a little bit about the major milestones in the company, how your grandfather came to Mexico in the 1950s and how…
Please can you tell our readers a little bit more about the history of Stendhal, and its major milestones along the way since its takeover in 1997? Stendhal is a…
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Big news last year; Takeda bought Nycomed in what has been seen as a game changing acquisition for the pharma world. How have you seen this acquisition affect Nycomed’s Latin…
The Mexican government has been fairly pro-active about promoting good practice such as the new drug registration process that helped eliminate drugs from the Mexican market that didn’t fulfill regulatory…
There have been quite a few regulatory changes in the last few years such as the new drug registration process and the suppression of the local plant rule. COFEPRIS has…
This is your 3rd interview with Focus Reports. What would you say has been the biggest change that has shaped the pharmaceutical industry since we last interviewed you in 2008?…
This is your third interview with Focus Reports. In 2004 and 2008 you were Director of AMIIF, before that you were Director of ANAFAM, and now we’re delighted to be…
See our Cookie Privacy Policy Here
